ClinicalTrials.gg
RecruitingNCT04498221LOOCUpdated Sep 19, 2024

Lymphatic Mapping Of Oropharyngeal Cancer

An interventional study of Imaging procedure and Surgical procedure in Oropharyngeal Cancer, sponsored by University College, London. Recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by University College, London · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Oropharyngeal Neoplasms with a site in United Kingdom — 4 open to participants now, 7 under way, 4 of them phase 3. Oropharyngeal Neoplasms · United Kingdom.

Planned enrollment
6th of 10
150 · median 205
Started
2022
the only one that year
No phase
4 of 14
1 open now
Registered
10th of 14
by date

Among the 14 studies in Oropharyngeal Neoplasms with a site in United Kingdom, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 4 with no phase, and was the 10th registered.

Oropharyngeal Neoplasms

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

Browse Oropharyngeal Neoplasms studies →

Open to participants now

4 of the 14 studies in Oropharyngeal Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Oropharyngeal Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

A multi-centre validation study to evaluate whether a new imaging and surgical protocol would work as well as the current gold standard in identifying sentinel nodes in patients with oropharyngeal cancer.

Read the detailed description

Cancer at the back of the mouth and throat is usually discovered after it has spread to lymph glands in the neck. Treatment therefore involves dealing with both the original tumour (in the mouth/throat) and the spread cancer in the lymph glands. This type of cancer sometimes spreads to both sides of the neck, not just the side on which the original tumour was located. The decision as to whether to treat the other side of the neck as well depends on various factors including the aggressiveness of the tumour, whether the patient smokes and whether or not the Human Papilloma Virus (HPV) is present in the tumour. This is inevitably inexact, and assessing the likelihood of the cancer spreading to the other side of the neck always involves an element of estimation. Some patients end up being treated unnecessarily on both sides (often with severe and lasting effects on swallowing, meaning they have to use a feeding tube), while others receive treatment on one side only but the cancer comes back on the other side.

This study will provide more accurate information on which to base the decision as to whether to treat the other side of the neck. The study will use a procedure known as sentinel node biopsy (SNB) to establish (with a high degree of accuracy) whether or not the cancer has spread to the other side of the neck. The study will be in two stages. The first stage is the imaging stage. A very low does of a radioactive tracer substance will be injected into the tumour. The radioactive tracers used in this study are either Human albumin colloidal particles or Lymphoseek. Once injected, they move quickly into the lymph nodes and can then be detected using a handheld gamma camera. The first nodes that the radiotracer moves into are the "sentinel" nodes. Patients already undergo an examination under anaesthetic (EUA); the patients participating in the study will have the radiotracer injected additionally and the sentinel nodes detected during this EUA. The use of the handheld camera is relatively new; so, all of the patients in the study will also have a CT scan the next day to double check whether the handheld camera identified the sentinel nodes correctly. The second stage of the study, the surgery stage, will involve a new group of patients having the imaging procedure. Those who do have sentinel nodes in the other side of the neck will have them removed during the EUA. Those nodes will then be examined thoroughly for signs of cancer. A separate limb of stage one of the study will involve some patients whose main tumours are easily accessible also having their tumour injected with the radiotracer a second time under local anaesthetic in an outpatient clinic. In the study this will take place several days after the initial injection with the radiotracer. If this procedure is found to be acceptable to patients, it would mean that patients could have the radiotracer injected before the EUA, thereby allowing time for the sentinel nodes to be identified by CT scan so that they can be removed during the EUA. This will provide a way to ensure that, even if the handheld camera cannot be used, the sentinel nodes can still be removed while the patient is under anaesthetic for the EUA. If the study is successful, the patient will be able to have much more accurate information about whether their cancer has, or might, spread to the other side of the neck, without having to undergo an additional general anaesthetic.

03

Conditions studied

  • Oropharyngeal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 or over
  • New diagnosis of OPC - all anatomical subsites and HPV status accepted
  • Unilateral nodes equating to AJCC TNM8 clinical staging N1-N2b for P16 negative and N1 for P16 positive patients.

Exclusion criteria

Exclusion Criteria:

  • Suspicious bilateral nodes on imaging
  • Previous radiotherapy or surgery to the neck
  • Second primary oropharyngeal tumours
  • Distant (e.g. lung, bone)
  • Pregnancy and lactation
  • Inability to give
  • Allergy to lymphatic tracers
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Imaging Phase

    During routine examination under anaesthetic 4 x peritumoural injection of investigator's choice of 99mTc-human albumin colloidal particles or Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan

    Procedure: Imaging procedure

  • Experimental
    Surgical Phase

    Excision of contralateral nodes identified on imaging \*(fhSPECT or SPECT/CT\*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.

    Procedure: Surgical procedure

Interventions

  • ProcedureImaging procedure

    During routine examination under anaesthetic 4 x peritumoural injection of investigator's choice of 99mTc-human albumin colloidal particles or Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan

  • ProcedureSurgical procedure

    Excision of contralateral nodes identified on imaging \*(fhSPECT or SPECT/CT\*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.

06

What researchers measure

Primary outcomes

  1. Rate of contralateral drainage

    Rate of contralateral drainage

    Time frame: 24 hours post injection

  2. Accuracy of detection of contralateral nodes by lymphoscintigraphy using fhSPECT compared to SPECT/CT

    Accuracy of detection of contralateral nodes by lymphoscintigraphy using fhSPECT compared to SPECT/CT

    Time frame: 24 hours post injection

  3. Number of contralateral nodes on SPECT/CT

    Number of contralateral nodes on SPECT/CT will be used as the denominator in calculating the sensitivity of fhSPECT in independently verified images

    Time frame: 24 hours post injection

  4. Number and location of contralateral nodes seen with lymphoscintigraphy performed by i) single injection ii) four peritumoural injections (standard practice) as assessed by paired SPECT/CT scans.

    Number and location of contralateral nodes seen with lymphoscintigraphy performed by i) single injection ii) four peritumoural injections (standard practice) as assessed by paired SPECT/CT scans.

    Time frame: 24 hours post injection

  5. Acceptability to patients assessed by questionnaire.

    Acceptability to patients assessed by questionnaire.

    Time frame: 24 hours post injection

  6. Occult metastasis rate of contralateral nodes (positive sentinel node biopsy).

    Occult metastasis rate of contralateral nodes (positive sentinel node biopsy).

    Time frame: 24 hours post injection

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No identifiable data will be shared with anyone outside the study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jan 2027, 54 months after the start.

Of 52 non-industry interventional studies with no phase under Oropharyngeal Neoplasms, half reached primary completion within 78 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 116. This study's planned 54 months is below that.

Counting every sponsor, half of 54 studies reached it within 78 months; a quarter within 27 and three quarters within 153.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2019
First posted
Aug 4, 2020
StartActual
Jul 7, 2022
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04498221
Collaborators
National Institute for Health Research, United Kingdom
Responsible party
Sponsor
First posted
Aug 4, 2020
Start date
Jul 7, 2022
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Sep 19, 2024

Study contacts

Trial Manager
Contact
ncita.looc@ucl.ac.uk
02076799274
Clare Schilling
principal investigator · University College, London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion